The Use of Genetic Markers to Determine Risk for Prostate Cancer at Prostate Biopsy
Authors:
Open Access
- 1 December 2005
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 11 (23) , 8391-8397
Abstract
Purpose: We examined a panel of 13 polymorphisms in 13 different genes to determine whether specific genotypes can help predict prostate cancer at the time of biopsy among men prescreened with prostate-specific antigen and digital rectal exam.Keywords
This publication has 32 references indexed in Scilit:
- Variation in patterns of practice in diagnosing screen‐detected prostate cancerBJU International, 2004
- Single Nucleotide Polymorphism of the Human Kallikrein-2 Gene Highly Correlates With Serum Human Kallikrein-2 Levels and in Combination Enhances Prostate Cancer DetectionJournal of Clinical Oncology, 2003
- Mutations in CHEK2 Associated with Prostate Cancer RiskThe American Journal of Human Genetics, 2003
- RNASEL Arg462Gln variant is implicated in up to 13% of prostate cancer casesNature Genetics, 2002
- Linkage between polymorphisms in the prostate specific antigen ARE1 gene region, prostate cancer risk, and circulating tumor cellsThe Prostate, 2002
- Serial Biopsy Results in Prostate Cancer Screening StudyJournal of Urology, 2002
- PROSPECTIVE EVALUATION OF PROSTATE CANCER DETECTED ON BIOPSIES 1, 2, 3 AND 4: WHEN SHOULD WE STOP?Journal of Urology, 2001
- FREQUENT GENOTYPE CHANGES AT −308, AND 488 REGIONS OF THE TUMOR NECROSIS FACTOR-α (TNF-α) GENE IN PATIENTS WITH PROSTATE CANCERJournal of Urology, 2000
- Elevated serum prostate specific antigen levels in conjunction with an initial prostatic biopsy negative for carcinoma: who should undergo a repeat biopsy?BJU International, 1999
- REPEAT SCREENING FOR PROSTATE CANCER AFTER 1-YEAR FOLLOWUP IN 984 BIOPSIED MENJournal of Urology, 1998